Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Biodesix (BDSX) EBT Margin (2019 - 2025)

Biodesix (BDSX) has disclosed EBT Margin for 7 consecutive years, with 14.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 2712.0% year-over-year to 14.0%, compared with a TTM value of 40.21% through Dec 2025, up 1973.0%, and an annual FY2025 reading of 40.21%, up 1973.0% over the prior year.
  • EBT Margin was 14.0% for Q4 2025 at Biodesix, up from 41.92% in the prior quarter.
  • Across five years, EBT Margin topped out at 14.0% in Q4 2025 and bottomed at 238.21% in Q1 2022.
  • Average EBT Margin over 5 years is 102.5%, with a median of 81.15% recorded in 2024.
  • The sharpest move saw EBT Margin surged 17226bps in 2021, then plummeted -21661bps in 2022.
  • Year by year, EBT Margin stood at 182.38% in 2021, then increased by 6bps to 171.13% in 2022, then skyrocketed by 63bps to 62.71% in 2023, then skyrocketed by 34bps to 41.12% in 2024, then soared by 66bps to 14.0% in 2025.
  • Business Quant data shows EBT Margin for BDSX at 14.0% in Q4 2025, 41.92% in Q3 2025, and 58.03% in Q2 2025.